Physician profile
Mary Larkin
NPI 1013056555
$2,290.84
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,892 · 2020: $156 · 2021: $243.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $419.47 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $326.82 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $268.92 | 2019 | |
| Ironshore Pharmaceuticals INC. | $235.49 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $193.08 | 2019 | |
| Alkermes, INC. | $185.73 | 2019-2021 | |
| Allergan, INC. | $183.04 | 2019 | |
| Vanda Pharmaceuticals INC. | $178.92 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $151.02 | 2019-2020 | |
| Tris Pharma INC | $83.71 | 2019 | |
| Lundbeck LLC | $53.59 | 2019-2020 | |
| Neuronetics, INC. | $11.05 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Larkin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.